Intercept Pharma (ICPT) Reports Q3 Loss of $3.04 Per Share

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($3.04), $2.22 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $77.6 million versus the consensus estimate of $73.74 million.

2022 Financial Guidance

We are updating our full year 2022 guidance:

• Increasing Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million from $325 million to $345 million.
• Narrowing non-GAAP adjusted operating expense guidance to $350 million to $365 million from $335 million to $365 million.
• This guidance includes our international business for the first six months of the year and our ongoing U.S. business for the full year.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?
• INVO Fertility (IVF) Tops Q2 EPS by 105c